The effect of elderberry syrup against COVID-19 symptoms

Phase 2

Recruiting

• Conditions: COVID-19, virus identified; U07.1; COVID-19 disease.

• Registration Number: IRCT20200406046965N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

A definitive diagnosis of COVID-19 infection based on laboratory confirmation (lymphocytopenia, increased quantitative CRP, chest X-ray results) and clinical symptoms of patients including fever, coughs and myalgia
Outpatients and home quarantined patients

Exclusion Criteria

Hospitalization
Age> 65 y and <18 y
Patients with catheter
Patients receiving chemotherapy drugs, corticosteroids and theophylline
Autoimmunity
Gastrointestinal diseases
Migraine
Diabetes
Hypokalemia
Myalgia
Respiratory diseases
Smoking
Pregnancy and breast feeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Thermometer.;Shortness of breath. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Autosaturation device, Counting the number of breaths in 1 minute.;Coughs. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.;Myalgia. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.

Secondary Outcome Measures

Name	Time	Method
ymphocytopenia. Timepoint: days 3, 7 and 14 after the intervention beginning. Method of measurement: Cell counter.;C-reactive protein. Timepoint: days 3, 7 and 14 after the intervention beginning. Method of measurement: CRP kit.